The role of loss of DNA sequences in carcinogenesis is a matter of considerable interest, especially since such allele loss may indicate the presence of a target suppressor gene within the lost region (Knudson, 1985) . A high frequency of loss on chromosome arm 17p has been reported in colorectal carcinomas (Fearon et al., 1987; Lothe et al., 1988; Delattre et al., 1989; Baker et al., 1989) , and one target of this loss has been shown to be the TP53 gene (for review, Levine et al., 1991) . Furthermore, most of the colorectal carcinomas with loss of one TP53 gene allele have revealed TP53 point mutations on the remaining allele (Baker et al., , 1990 Nigro et al., 1989) , resulting in a functionally inactive TP53 gene. However, the chromosomal extent of the loss comprising the TP53 gene locus, and thereby the relevance of loss detected on chromosome arm 17p as a reflection of changes of the TP53 gene, is not similarly well characterised.
Allele amplification in colorectal carcinomas has so far not been extensively studied by Southern analysis. The reason might be that this genetic alteration is less frequently observed than loss of heterozygosity, and because the concept of tumour suppressor genes implies loss rather than gain of DNA sequences. We have recently demonstrated allele amplification within the Rb gene in 30% of colorectal carcinomas (Meling et al., 1991) , suggesting a role also for amplified genes in carcinogenesis in the colorectum.
The aim of this study was to analyse the frequency of loss of the TP53 gene in a large series of colorectal carcinomas, and to evaluate whether loss of this gene was part of local, or whole chromosome loss. We have also studied the carcinomas with regard to allele loss and allele amplification at other loci on chromosome 17.
Materials and methods
Patients and tumour samples Fresh tissue samples from 231 patients with colorectal adenocarcinomas removed during laparotomy, were studied. Six patients had more than one carcinoma synchronously, and from these patients, only one tumour was studied to exclude bias from mutual dependence of synchronous tumours. The 119 male patients had a mean age of 68 years (range 26 to 94 years), and the 112 female patients had a mean age of 69 years (range 24 to 92 years). Dukes' stage and tumour site are given in Table I .
Cell suspensions were mechanically prepared by mincing tumour samples in phosphate-buffered saline (PBS) followed by nylon mesh filtration (mesh pore size 70 tm) (Seidengazefabrik AG Thal, Switzerland). The cells were both fixed and stored in 70% ethanol at 4°C, until DNA extraction was performed. The degree of contamination of normal cells in the tumour cell suspensions has recently been estimated by cytological examination of cytospin preparations (Meling et al., 1991) . The cell suspensions contained a mean of 84% tumour cells, ranging from 62% to 97%.
Southern analysis
Nuclear DNA was extracted from tumour cells and from peripheral blood leucocytes in a 340A Nucleic Extractor (Applied Biosystem, Rotterdam, Netherlands), principally using standard methods (phenol-chloroform extraction and ethanol precipitation) (Kunckel et al., 1977) . DNA samples (7.5 pg) were digested to completion with approximately eight times excess of the restriction enzymes BamHI, TaqI, aAccording to the modified Dukes' classification (Dukes, 1932; Turnbull et al., 1967 (Southern, 1975) , using alkaline solution (0.4 M NaOH and 0.6 M NaCl). Hybridisation was performed using the probe pBHP53 (locus symbol TP53) which detects a BamHI-polymorphism located on chromosome band 17p 13.1 and telomeric to the TP53 gene (H0yheim et al., 1989, B. H0yheim, personal communication, 1991) . The probe pYNZ22 (D17S30), detecting a VNTR polymorphism on 17p 13.3 (Nakamura et al., 1988a) , was hybridised to BamHI-digested DNA. The probe pTHH59 (D17S4), detecting a VNTR polymorphism on 17q 23-q 25.3 (Nakamura et al., 1988b ) was hybridised to PvuII-digested DNA, and the probe pRMU3 (D17S24), detecting a VNTR polymorphism on 17q 23-q 25.3 (Myers et al., 1988 , HGMII, 1991 , was hybridised to TaqI-digested DNA. Probe locations are shown in Figure 1 .
The probes were radioactively labelled with [ax32P]dCTP according to the random labelling method (Feinberg & Vogelstein, 1983 (Nakamura et al., 1988c) , and pYNH24 hybridising to chromosome arm 2p (Nakamura et al., 1987) were applied. Allele loss was defined as a reduction of 33% or more in hybridisation intensity (Chen et al., 1991 , Meling et al., 1991 , compared with the intensity of the normal allele. Allele amplification was defined as a 50% or more increase in hybridisation intensity (Meling et al., 1991 Table IV ). Significantly more tumours had loss restricted to 17p (41%, 77 cases), than loss on both 17p and 17q (28%, 52 cases) (P <0.001) (Table III) .
Of the total number of carcinomas analysed, 79 cases were informative with both probes used on chromosome arm 17p. When loss was demonstrated with pYNZ2, pBHP53 also always showed loss (n = 45), whereas when loss was demonstrated with pBHP53, only 45 of 54 (83%) showed loss with pYNZ22 (for the association between loss at these two loci, P <0.0001).
In the tumours with amplification on 17p, the mean increase in hybridisation intensity found at the two loci on 17p was 160% (range 50% to 300%).
Allele alterations at 17q loci Loss on chromosome arm 17q was demonstrated in 34% of the tumours (64 cases), amplification in 15% (29 cases) (Table III) , and both loss and amplification in 6% of the tumours (12 cases). No association was found between loss on 17q and amplification on the other 17q arm (Table IV) . Significantly more tumours had loss on both 17q and 17p (28%, 52 cases) than loss restricted to 17q (6%, 12 cases) (P <0.0001).
Of the total number of carcinomas analysed, 115 cases were informative with both probes used on chromosome arm 17q. Amplification on 17q was detected with only one of two informative probes in 11% cases (13/115), and with both probes in 6% cases (7/115).
In the tumours with amplification on 17q, the mean increase in hybridisation intensity found at the two loci on 17q was 90% (range 50% to 190%).
Inter-relation among alterations on chromosome 17 A significant association was found between loss on 17p and loss on 17q P <0.01 (Table II) (Table III) . Amplification on 17q was not significantly associated with loss on 17p (Table IV) . At the level of the two individual loci on 17q, amplification of one allele was associated with loss of the other allele at the locus detected with pTHH59 (P <0.05), but not at the locus detected with pRMU 3 (data not shown).
Intratumoural homogeneity
In seven of ten carcinomas, no intratumoural variation was found, and in three carcinomas, a difference was found at one of the four loci analysed. In one carcinoma, loss was detected by the probe pYNZ22 in four of five samples. In this carcinoma, the two other informative probes showed loss in all samples (indicating whole chromosome loss in all samples). In one carcinoma, the probe pRMU3 detected allele amplification in both samples, but loss of the other allele in only one of them. In one carcinoma, allele amplification was detected with pRMU3 in one sample, whereas in the other sample, the increase in hybridisation did not reach the cut-off value of 50%.
Discussion
In this study of 231 colorectal carcinomas, loss was the most frequent alteration found on chromosome arm 17p, and could be detected in 68% of the carcinomas. In the majority of these carcinomas (41% of the total number of informative cases), the loss was found only on this chromosome arm.
Studies of breast cancer have demonstrated an increase in the frequency of allele loss on 17p with increasing distance from the TP53 gene locus to the telomeric end of the chromosome arm, suggesting the existence of a tumour suppressor gene on the distal part of 17p (Coles et al., 1990; Sato et al., 1990; Andersen et al., 1992) . From the present study on colorectal carcinomas, the frequency of loss, as detected with the probe pYNZ22, was lower than the frequency of loss detected with the probe pBHP53, although not significantly so. When both these probes were informative, every loss detected with the probe pYNZ22 was also detected with pBHP53. These findings argue against tumour suppressor gene(s) located distal to the TP53 gene on chromosome arm 17p involved in colorectal carcinogenesis. Furthermore, these data clearly show that loss detected by either of these probes can be regarded as loss of the TP53 gene. Thirty-four per cent of the carcinomas had loss on 17q. Loss on 17q was strongly associated with loss of the TP53 gene, suggesting that loss on 17q is frequently part of a more extensive deletion that also comprises the TP53 gene, most likely a part of a whole chromosome loss. The tumours with loss on 17q not involving the TP53 gene constituted 6% of the tumours. This low frequency most likely reflects that loss on 17q is unspecific in these tumours. However, we cannot rule out that among the tumors not showing allele loss on 17q, there may be tumours having abnormalities at a more proximal site of this chromosome arm.
In general, allele amplification may indicate a specific genetic change contributing in the carcinogenesis, or a compensatory mechanism as response to a specific event, as for instance loss of chromosomal segments (Cavenee et al., 1983) . Fifteen per cent of the tumours studied had amplification on 17q, and a net gain of DNA sequences on 17q was seen in the majority of these tumours. A gain of chromosome arm 17q in tumours with loss on 17p has earlier been found in colorectal carcinomas by cytogenetic analysis (Muleris et al., 1985 (Muleris et al., , 1988 . In our study, the amplification on 17q was neither associated with loss on 17p, nor with loss on the other 17q arm. This is in contrast to a previous report using Southern analysis, demonstrating that gain of one 17q allele was always followed by loss of the other allele (Fearon et al., 1987) . Amplification on 17p, found in a small proportion of the tumours (8%), always occurred in combination with loss on the other 17p arm. This is in agreement with earlier reports, demonstrating that monosomy is an unstable condition, and single chromosomes tends to be duplicated after loss has occurred of the other homologue chromosome (Eves et al., 1983; Cavenee et al., 1983) . However, since amplification on 17p was associated with loss on the homologue chromosome arm, whereas amplification on 17q
was not, different chromosomal mechanisms associated with monosomy of 17p and of 17q may be indicated. The relatively high frequency of amplification on 17q addresses the possibility that amplification on 17q is a specific and not just a random chromosomal event in colorectal carcinomas. This question, however, needs further clarification.
In summary, loss of the TP53 gene was found in the majority of the colorectal carcinomas, and was most frequently part of a limited, subchromosomal deletion, as oppossed to being part of a whole chromosome loss. Furthermore, we found no evidence for any additional tumour suppressor gene on chromosome 17 involved in colorectal carcinogenesis. We therefore conclude that loss of the TP53 gene, as detected by Southern analysis and the two probes on 17p applied, denotes specific loss of this gene, and furthermore, that this loss is of functional importance for the tumours with this change. To analyse the implications of loss of the TP53 gene in colorectal carcinogenesis, we have studied the relationship between loss of the TP53 gene and clinicopathological variables of established prognostic importance. This analysis is presented in article II (Meling et al., 1992) .
